Home Cardiac arrest AED use varies by race and geography
Cardiac arrest
AED use varies by race and geography
Racial and Geographic Disparities in Automated External Defibrillator Use During EMS Encounters in the United States
Healthcare · Added 21 May 2026
Analysis of AED deployment patterns during EMS encounters revealing racial and geographic differences in defibrillator access and application.
- Study type
- Cross-sectional
- Design
- Descriptive cross-sectional analysis of aggregated national EMS data
- Participants
- 106,246 EMS encounters across six racial/ethnic groups
- Main finding
- AED applied in 16,688 encounters (15.7%); rates varied by race and geography, with lowest use in White patients and markedly lower use in suburban and frontier areas
- Caveat
- Aggregated public data cannot distinguish true inequity from case or system factors
- Bottom line
- Context only
Learning goal
Understand how community access barriers affect early defibrillator use in out-of-hospital cardiac arrest.
More
- Topic: Cardiac arrest
- Daily scan: 21 May 2026
Related papers on Cardiac arrest
-
Geolocation recruits responders to defibrillators
This study evaluated whether a geolocation system can recruit volunteer first responders to nearby defibrillators in real time, and found it successfully mobilised responders and shortened time to first shock compared with historical controls.
-
System failure drives poor OHCA outcomes in India
This commentary argues that poor resuscitation outcomes in India are driven by prehospital system failures rather than individual provider limitations, highlighting the need for structural reforms in emergency response infrastructure and training.
-
EMS volume doesn't affect traumatic arrest outcomes
Retrospective cohort examining whether higher EMS encounter volume is associated with better management and outcomes in prehospital traumatic cardiac arrest.
-
DSED use rising but still low after DOSE VF
Nationwide observational study examined trends in DSED use for refractory VF before and after publication of the DOSE VF trial.